Abstract
In this issue of Heart, Lung and Circulation, Hutchens et al. report the trends of oral anticoagulant use and antiplatelet use in patients with atrial fibrillation (AF).
Alarmingly, by the end of the study, only 45% of high-risk patients, in whom the guidelines currently recommend oral anticoagulation (OAC) therapy, were receiving OAC therapy. This seems surprising, compared to what we perceive the rates to be in our own cardiology practice...
Alarmingly, by the end of the study, only 45% of high-risk patients, in whom the guidelines currently recommend oral anticoagulation (OAC) therapy, were receiving OAC therapy. This seems surprising, compared to what we perceive the rates to be in our own cardiology practice...
Original language | English |
---|---|
Pages (from-to) | 935-936 |
Number of pages | 2 |
Journal | Heart, Lung and Circulation |
Volume | 30 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2021 |
Keywords
- Antiplatelet agents
- Atrial fibrillation
- Guidelines
- Oral anticoagulants
- Stroke prevention